Bladder CancerPatients with Lynch Syndrome Mismatch Repair Gene Mutations Are at Higher Risk for Not Only Upper Tract Urothelial Cancer but Also Bladder Cancer
Introduction
Previous studies have suggested a hereditary factor in bladder cancer (BCa), urothelial carcinoma (UC) type, with first-degree relatives having an approximately 2 times increased risk [1], [2]. It is uncertain whether this finding represents evidence of a genetic and/or shared environmental basis for familial aggregation. Recently, several gene variants have been shown to confer susceptibility to BCa [3], [4].
Epidemiological studies have demonstrated inheritance for upper tract UC (UTUC). Lynch syndrome (LS), or hereditary nonpolyposis colorectal cancer (HNPCC), is an autosomal-dominant familial cancer syndrome caused by germline mutations in the DNA mismatch repair (MMR) genes mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) (MSH2); mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) (MLH1); mutS homolog 6 (E. coli) (MSH6); and PMS2 postmeiotic segregation increased 2 (S. cerevisiae) (PMS2) [5]. Defective MMR function leads to genetic instability, detected as novel alterations in microsatellite regions of DNA, which are short, repetitive sequences (one to five nucleotides) located throughout the genome [6]. Microsatellite instability (MSI) is a hallmark feature seen in approximately 85% of LS-associated tumors in mutation carriers [7]. Immunohistochemistry (IHC) is another tool used to recognize LS, with 95% sensitivity for detecting the absence of expression of MMR proteins. Individuals with familial clustering of colorectal and other LS-associated tumors are generally referred to predictive genetic testing programs for screening of germline MMR gene mutations.
LS patients are at an increased risk for other extracolonic cancers such as endometrial cancer (27–71%), gastric cancer (2–13%), ovarian cancer (3–13%), and of interest to urologists, UTUC [8]. Studies about the risk of BCa in LS have been limited [9]. The goal of this study was to further investigate the risk of bladder UC in LS patients, in addition to the already reported increased risk for UTUC.
Section snippets
Study subjects
The Familial Gastrointestinal Cancer Registry (FGICR) (Mount Sinai Hospital, Toronto, Ontario, Canada) comprises families in Ontario diagnosed with rare forms of inherited gastrointestinal cancers who consent to be included. The registry was analyzed to isolate a subset of patients with confirmed MMR mutations in MLH1, MSH2, MSH6, or PMS2 genes from 1980 to 2007. The Research Ethics Board approved all study protocols. All confirmed mutation carriers were reviewed for a history of cancer of the
Patient population
A total of 321 patients were identified with confirmed MMR gene mutations. Germline MSH2 and MLH1 mutations were the most common, whereas MSH6 and PMS2 mutations were rare (Table 1).
Eleven of 177 patients with MSH2 mutations (6.21%) had confirmed BCa (Table 2), which was significantly above the average rate expected in the general population compared with gender- and age-specific lifetime risks obtained from Canadian Cancer Statistics 2011 (3.6% for men and 1.2% for women, p < 0.001). The average
Discussion
The increased incidence of UC in LS was first reported by Vasen et al. in 1990 [14], with eight patients from four families being diagnosed. Subsequent studies investigating the tumor spectrum of families meeting the Amsterdam criteria or Bethesda criteria have supported this finding, with an increased risk of 4–17 times and 8–22 times seen for renal pelvis and ureter UC, respectively [15], [16], [17]. MSH2 mutation carriers have a significantly higher risk of UC compared with MLH1 carriers,
Conclusions
Our study suggests that family members of LS patients with MSH2 mutations are at an increased risk not only for UTUC but also for BCa. First-degree relatives from MSH2 mutation families, as well as patients with known MSH2 mutations, could be offered screening for UCs.
References (29)
- et al.
Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (Lynch syndrome) tumor spectrum
Eur Urol
(2008) - et al.
New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC
Gastroenterology
(1999) - et al.
Urinary tract cancer and hereditary nonpolyposis colorectal cancer: risks and screening options
J Urol
(1998) - et al.
Microsatellite instability in urothelial carcinoma of the upper urinary tract
J Urol
(2003) - et al.
Infrequent microsatellite instability in urothelial cell carcinoma of the bladder in young patients
Eur Urol
(2006) - et al.
Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance
J Urol
(2006) - et al.
Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) program
Oncologist
(2007) - et al.
Familial aggregation of urothelial cell carcinoma
Int J Cancer
(2002) - et al.
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary BCa
Nat Genet
(2009) - et al.
A sequence variant at 4p16.3 confers susceptibility to urinary BCa
Nat Genet
(2010)
The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside
Fam Cancer
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability
J Natl Cancer Inst
Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer)
J Med Genet
Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers
J Med Genet
Cited by (85)
The molecular-morphologic correlates of bladder cancer
2023, Diagnostic HistopathologyIncidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition Syndromes
2022, Clinical Genitourinary CancerGenitourinary manifestations of Lynch syndrome in the urological practice
2022, Asian Journal of UrologyCitation Excerpt :Conversely, Barrow et al. [12] did not observe a significant predisposition to BCa development for any MMR mutation compared to the general population. Skeldon et al. [37] identified 14 out of 321 (4%) LS patients experiencing BCa during a median follow-up of 9 years. Overall, one patient had BCa diagnosed first; one patient had UTUC diagnosed first; and four patients experienced BCa and UTUC synchronously.
Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma
2020, Genetics in Medicine